This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drake, W. M. Articles by Orwoll, E. S. Search for Related Content PubMed PubMed Citation Articles by Drake, W. M. Articles by Orwoll, E. S.

An Investigation of the Predictors of Bone Mineral Density and Response to Therapy with Alendronate in Osteoporotic Men

Osteoporosis Research Centre (W.M.D., D.L.K.), University of British Columbia, Vancouver, British Columbia, V5Z 2K4 Canada; St. Joseph Hospital (C.J.R.), Bangor, Maine 04401; and Bone and Mineral Research Unit (E.S.O.), Oregon Health and Science University, Portland, Oregon 97201

Address all correspondence and requests for reprints to: Dr. W. M. Drake, Department of Endocrinology, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. E-mail: w.m.drake{at}qmul.ac.uk.

Male osteoporosis is an important disease, with 25–30% of all hip fractures occurring in men. In a recent randomized, placebo-controlled study of osteoporotic males, alendronate 10 mg daily for 2 yr led to significant increments in bone mineral density (BMD), of a similar magnitude to those observed in postmenopausal women. In this study, specimens collected at intervals during the recent trial of alendronate in male osteoporosis, from 197 of the original 241 participants, were assayed for testosterone, estradiol, IGF-I, IGF binding protein 3 (IGFBP-3), bone-specific alkaline phosphatase [BSAP (serum)], and N-telopeptide of type I collagen corrected for creatinine [NTx (urine)]. Together with fracture and densitometry data from the original study, relationships were examined between BMD and serum IGF-I, IGFBP-3, testosterone, estradiol, BSAP, and urine NTx, both at baseline and during treatment with alendronate, to gain possible insights into the pathogenesis of male osteoporosis. Statistically significant (P 0.05) associations were documented, at baseline, between the presence of vertebral fracture and each of serum IGF-I, serum IGFBP-3, serum free testosterone, total spine BMD, and total body BMD. No statistically significant correlations were observed between any of the baseline variables (IGF-I, IGFBP-3, estradiol, testosterone, and presence of vertebral fracture) and the BMD response to alendronate at any site. In a multivariate analysis, used to identify possible combinations of factors capable of predicting baseline BMD or response to alendronate, statistically significant (P 0.01) relationships were seen, at baseline, between BMD and body mass index, age, and prior fracture. However, no statistically significant relationships were seen between any of the baseline variables (age, body mass index, testosterone, estradiol, IGF-I, IGFBP-3, and prior fracture) and change in BMD at any site. These data suggest that among men with osteoporosis it is not possible to identify patients who would be particularly good candidates for therapy with alendronate on the basis of biochemical or hormonal markers. Alendronate therapy appears to benefit osteoporotic males equally, irrespective of baseline serum testosterone, estradiol, IGF-I, or markers of bone turnover.

This study was supported by an unrestricted Medical Schools grant from Merck (Frosst, NJ).

Abbreviations: BMD, Bone mineral density; BMI, body mass index; BSAP, bone-specific alkaline phosphatase; IGFBP-3, IGF binding protein 3; NTx, N-telopeptide of type I collagen corrected for creatinine; PMO, postmenopausal osteoporosis.

This article has been cited by other articles:

				H. A. Fink, S. K. Ewing, K. E. Ensrud, E. Barrett-Connor, B. C. Taylor, J. A. Cauley, E. S. Orwoll, and for the Osteoporotic Fractures in Men Study Group Association of Testosterone and Estradiol Deficiency with Osteoporosis and Rapid Bone Loss in Older Men J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3908 - 3915. [Abstract] [Full Text] [PDF]